Siemens Eclipse HP Cyclotron for PET Imaging Research

描述(由申请人提供)：该提案请求为西门子日食高压回旋加速器提供资金，以支持一个非常成功的正电子发射断层扫描(PET)成像研究项目，该项目自1992年以来一直在匹兹堡大学运行。这一充满活力的研究计划目前得到了NIH资助的28项拨款以及几个基金会和行业支持的研究项目的支持，这些项目来自匹兹堡大学医学院8个学术部门的25名研究人员。该团队拥有令人印象深刻的出版记录，并取得了翻译研究的成功，例如开发了PET/CT扫描仪和淀粉样显像剂[11C]匹兹堡化合物B(PIB)，目前正在全球范围内用于阿尔茨海默病的研究和临床试验。Eclipse HP将取代1992年安装的旧西门子RDS-112回旋加速器，该加速器已被制造商宣布报废，仅保留有限的可维护性。回旋加速器是任何PET研究计划的关键设备，因为大多数项目摘要中使用的放射性核素的半衰期很短，需要现场生产。RDS-112的失败将对NIH赞助的正在进行的研究造成重大和有害的中断。除了对现有基础设施进行关键升级外，Eclipse HP系统的几个功能还将显著增强PET研究计划。Eclipse HP电磁铁的深谷设计改善了光束传输，降低了内部激活水平，并提高了产量，而单线圈磁铁设计显著降低了功耗。拟议的Eclipse HP配置的第二个优势是使用双4位置目标传送带，总共有8个目标。目前的RDS-112系统有四条固定的光束线，每条线只有一个固定的目标--因此限制了目标的利用。拟议的Eclipse HP配置中靶数量的增加以及双靶照射的灵活性将代表着我们放射性核素生产能力的显著改善。所要求的附件包括用于生产[11C]MEI的远程自动化气相系统和碳-11和氟-18的掺入平台，使我们能够通过快速实现系列放射性药物生产的周转时间来实现新回旋加速器的最大效率。实现这些效率是至关重要的，因为RDS-112目前为两台西门子HR+PET扫描仪和两台临床前microPET扫描仪提供放射性药物。本提案中描述的19个主要用户项目和3个小型用户项目将受益于一个现代化的、目前得到支持的回旋加速器的选址，该回旋加速器将在可预见的未来保持PET设施的放射性药物生产能力。此外，日食HP的放射性核素生产能力的增加将使现有的PET扫描仪得到更充分的利用，从而产生更多的研究成果，并将支持继续扩大在该机构进行的PET成像研究的范围。 公共卫生相关性：西门子日食惠普回旋加速器要求生产短寿命的放射性材料，以支持匹兹堡大学一个非常成功的正电子发射断层扫描(PET)成像研究计划，该计划目前得到了NIH资助的28项赠款的支持，这些赠款将PET成像用于各种疾病的新型生物医学研究。所要求的回旋加速器和附件将取代1992年安装的旧回旋加速器，该回旋加速器不再得到供应商的支持，并有助于提高聚酯设施的生产能力。如果获奖，这项提案预计将对美国在该机构(创造4-5个新工作岗位，保持40个以上工作岗位)和供应商(西门子及其供应商保留75个以上工作岗位)的工作岗位产生重大影响，同时实现相当于13个普通美国家庭用电量的能源节约。

DESCRIPTION (provided by applicant): This proposal requests funds for a Siemens Eclipse HP Cyclotron in support of a highly successful positron emission tomography (PET) imaging research program that has been operational at the University of Pittsburgh since 1992. This vibrant research program is presently supported by 28 NIH-funded grants as well as several foundation and industry supported research projects from a group of 25 investigators from 8 academic departments of the University Of Pittsburgh School Of Medicine. This group has an impressive record of publication and achieving translational research successes such as the development of the PET/CT scanner and the amyloid imaging agent [11C]Pittsburgh-compound B (PiB) that is now being used worldwide in Alzheimer's disease research and clinical trials. The Eclipse HP will replace a legacy Siemens RDS-112 cyclotron, installed in 1992, which has been declared end-of-life by the manufacturer and retains only limited serviceability. The cyclotron is a key piece of equipment for any PET research program as the radionuclides used in a majority of the included project summaries have short half-lives that necessitate on-site production. Failure of the RDS-112 would represent a significant and detrimental interruption to ongoing NIH-sponsored research. In addition to providing a critical upgrade to existing infrastructure, several features of the Eclipse HP system will significantly enhance the PET research program. The deep-valley design of the Eclipse HP electromagnets provides improved beam transmission, reduced levels of internal activation, and higher production yields, while the single-coil magnet design drastically reduces power consumption. A second advantage of the proposed Eclipse HP configuration is the use of dual 4-position target carousels for a total of eight targets. The current RDS-112 system has four fixed beam lines, each with only one stationary target- thus limiting target utilization. The increased number of targets in the proposed Eclipse HP configuration as well as flexibility in dual target irradiation will represent a dramatic improvement in our radionuclide production capacity. The requested accessories, which include a remote automated gas-phase system for the production of [11C]MeI and incorporation platforms for both carbon-11 and fluorine-18, will allow us to realize the maximum efficiencies of the new cyclotron by enabling quick turnaround times for serial radiopharmaceutical productions. Realizing these efficiencies is of paramount importance as the RDS-112 presently supplies radiopharmaceuticals for two human Siemens HR+ PET scanners and two preclinical microPET scanners. The 19 major and 3 minor user projects described in this proposal will benefit from the sitting of a modern and currently supported cyclotron that will maintain the radiopharmaceutical production capabilities of the PET Facility for the foreseeable future. In addition, the increased radionuclide production capacity of the Eclipse HP will allow existing PET scanners to be more completely utilized, resulting in a greater output of studies, and will support continued expansion of the scope of PET imaging research conducted at the institution. PUBLIC HEALTH RELEVANCE: The Siemens Eclipse HP cyclotron requested will produce short-lived radioactive materials in support of a highly successful positron emission tomography (PET) imaging research program at the University of Pittsburgh, which is presently supported by 28 NIH funded grants that use PET imaging in novel biomedical investigations across a spectrum of diseases. The requested cyclotron and accessories will replace a legacy cyclotron installed in 1992 that is no longer supported by the vendor and facilitate a much needed increase in the PET Facility's production capacity. If awarded, this proposal is expected to have a significant impact on American jobs both at the institution (4-5 new jobs created, 40+ jobs maintained) and at the vendor (75+ jobs maintained at Siemens and its suppliers), while realizing an energy savings in terms of electricity use that is equivalent to the usage of 13 average American households.